Background: There are no systems for the rapid diagnosis and prognosis of acute pancreatitis in the Emergency Department. Our aim was to evaluate whether the combined use of serum lipase and interleukin-6 or serum lipase and C-reactive protein is able to simultaneously establish both the diagnosis and the prognosis of acute pancreatitis. Methods: Eighty patients with acute abdomen were studied on admission to the Emergency Room. Forty patients had nonpancreatic acute abdomen, and 40 had acute pancreatitis (25 had mild acute pancreatitis and 15 had severe pancreatitis). Forty healthy subjects comparable for sex and age were also studied as controls. Lipase, interleukin-6, and C-reactive protein were determined on serum in all subjects. Results: Using lipase to discriminate between patients with nonpancreatic acute abdomen and patients with acute pancreatitis (cutoff values ranging from 419 to 520 U/L), one patient with acute pancreatitis was not identified correctly. To discriminate between patients with severe acute pancreatitis and those with mild pancreatitis in the remaining 39 patients, interleukin-6 (cutoff value, <3.7 g/L) had a sensitivity of 100% (15 of 15) and a specificity of 83% (20 of 24); 75 of 80 (94%) patients were classified correctly. C-reactive protein (cutoff values ranging from 6 to 7 mg/L) showed a lower prognostic efficiency than interleukin-6: sensitivity of 87% (13 of 15) and specificity of 46% (11 of 24). Sixty-four of 80 patients (80%) were classified correctly. The area under the ROC curve for interleukin-6 (0.911 ؎ 0.049) was
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Conclusion:
The combined use of serum lipase and interleukin-6 is useful in simultaneously establishing both the diagnosis and the prognosis of acute pancreatitis.
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There are no systems for the rapid diagnosis and prognosis of acute pancreatitis in the Emergency Department. Simple tests are needed to orient the diagnostic efforts toward establishing the nature of abdominal pain and to simultaneously indicate the severity of acute pancreatitis. Currently, the common specific indices used for evaluating the severity of acute pancreatitis, such as Ranson's score or the Glasgow score (1, 2 ) , are not useful in an emergency situation. We have shown previously that the combined use of serum lipase, either with ␤ 2 -microglobulin or with C-reactive protein (CRP), 1 was not useful in simultaneously evaluating the diagnosis and the prognosis of acute pancreatitis (3 ) . A rapid assay to determine the serum concentrations of interleukin-6 (IL-6) is now available for routine use in clinical practice (4 ) . Serum IL-6 has been shown to be a useful index of the severity of acute pancreatitis (4 -7 ) . However, no studies have been carried out to evaluate whether the combined use of serum lipase and serum IL-6 can simultaneously diagnose acute pancreatitis and predict its severity. The aim of this study was to explore this possibility. The combined use of lipase and serum CRP was also assessed for comparison.
were prospectively studied on admission to the Emergency Room from August 1997 to April 1998. Diagnosis of acute pancreatitis was based on a history of prolonged abdominal pain and was confirmed by abdominal ultrasonography and/or contrast enhanced computed tomography. Lipase determination was not used for the diagnosis of acute pancreatitis. Thirty-six patients were studied at the onset of the disease, 3 on the second day of illness, and the remaining 1 on the fourth day. The pancreatitis was of biliary origin in 28 patients; the biliary origin of acute pancreatitis was suggested by laboratory data (increased serum concentrations of conjugated bilirubin, transaminases, and alkaline phosphatases), by a history of gallstones, and by the presence of a dilated common bile duct and biliary sludge and/or stones at ultrasonography and/or computed tomography and/or endoscopic retrograde cholangiography. Alcohol abuse (mean daily pure alcohol intake Ͼ80 g) was the etiological factor in 7 patients; acute pancreatitis was associated with pancreas divisum in 2 patients and was of unknown origin in the remaining 3 patients. According to the Atlanta criteria (8 ), 25 patients had mild acute pancreatitis and 15 patients had the severe form of the disease. The classification was performed without knowledge of the results of the tests under investigation. The complications in patients with severe acute pancreatitis are listed in Table 1 .
Forty patients admitted to the Emergency Room in the same period (August 1997 through April 1998) with a diagnosis of acute abdomen of nonpancreatic origin were also studied (20 men and 20 women; mean age, 53 years; range, 22-97 years). For each acute pancreatitis patient admitted to the study, one patient with an acute abdomen of nonpancreatic origin was enrolled. Final diagnoses are listed in Table 2 .
Patients who had not given informed consent, those with psychoses, as well as those with a history of malignancies, chronic renal and hepatic insufficiency, and chronic pancreatitis were excluded from the study. Forty healthy subjects, randomly selected in the same time period from blood donors and subjects who underwent medical check-ups, were also studied; there were 26 men and 14 women (mean age, 54 years; range, 18 -82 years). They had been screened by means of an interview, physical examination, and routine blood analysis and showed no evidence of illness. No significant differences in gender and age were found among the three groups of subjects studied.
After all subjects had given informed consent, a blood sample was obtained from each patient in the Emergency Room at the initial visit and from each healthy subject the morning after an overnight fast. The sera were kept frozen at Ϫ20°C until analysis.
Lipase, IL-6, and CRP were determined on the serum of all subjects studied using commercially available reagents. Assays were performed without knowledge of the patients' findings or other test results. Lipase was determined using a turbidimetric assay (DuPont; reference interval, 24 -270 U/L) (9 ). The lower limit of detection was 5 U/L, and the calibration curve ranged from 0 to 1200 U/L; the mean recovery was 102%. The within-run imprecision (CV, n ϭ 20) was 3.3% at 270 U/L and 2.8% at 810 U/L, whereas the day-to-day imprecision (10 determinations) was 7.3% at 270 U/L and 6.5% at 810 U/L. Serum IL-6 was determined using an ELISA kit (Predicta IL-6 ELISA kit; Genzyme Co.). The lower limit of detection was 2 g/L, and the calibration curve ranged from 0 to 512 g/L; the mean recovery was 102%. The within-run imprecision (CV, n ϭ 20) was 8% at 60 g/L and 4% at 300 g/L, whereas the day-to-day imprecision (10 determinations) was 10% at 60 g/L and 5.4% at 810 g/L. With this assay, healthy subjects had no detectable IL-6 in serum (4 ) . CRP was determined using a nephelometric technique (Beckman, Inc.; reference interval, 0 -8 mg/L) (10 ). The lower limit of detection was 1 mg/L, and the calibration curve ranged from 1 to 120 mg/L; the mean recovery of added CRP was 103%. The within-run imprecision (CV, n ϭ 20) was 3% at 10 mg/L and 2% at 60 mg/L, whereas the day-to-day imprecision (10 determinations) was 7% at 10 mg/L and 4% at 60 mg/L.
statistical analysis
ROC curves and the respective areas under the curves were calculated for each marker to provide information about the accuracy of serum lipase in distinguishing between patients with acute pancreatitis and those with nonpancreatic acute abdomen and about the accuracy of both serum IL-6 and CRP in distinguishing severe acute pancreatitis from the mild form of the disease. Nonparametric estimates of the areas under the ROC curves and the respective SEs were applied (11 ) . A procedure involving paired data was applied to compare areas under the ROC curves (12 ) . The best cutoff was chosen as the value that maximized the likelihood ratio (LR) obtained using the following formula: LR ϭ (probability of true positive ϩ probability of true negative)/ (probability of false positive ϩ probability of false negative) (4 ). The best cutoff values are reported as ranges in which the diagnostic performance of the method does not change. Using these cutoff values, we calculated the sensitivity, specificity, and the percentage of correct results in simultaneously establishing the diagnosis (acute pancreatitis patients vs patients with nonpancreatic acute abdomen) and prognosis (severe vs mild acute pancreatitis patients) of acute pancreatitis for serum lipase, IL-6, and CRP. The exact 95% confidence intervals (CIs) of these proportions were also evaluated (13 ) . The Yates-corrected 2 and the Mann-Whitney U-test were applied to compare different groups of subjects. All statistical evaluations were performed running the SPSS/PCϩ statistical package on a personal computer (14 ) . A two-tailed P Ͻ0.05 was used to define statistical significance.
Results
The individual values of serum lipase, IL-6, and CRP in patients with acute pancreatitis, in those with nonpancreatic acute abdomen, and in healthy subjects are reported in Fig. 1 . Serum lipase concentrations were higher than the upper limit of normal in all patients with acute pancreatitis, in three patients with acute abdomen of other etiologies (7.5%; CI, 1.6 -20%; one patient had a duodenal ulcer, one had gallstones, and one had an intestinal obstruction because of an inguinal hernia), and in two healthy subjects (5%; CI, 0.6 -17%). Serum IL-6 concentrations were abnormally high in all (100%; CI, 78 -100%) of the 15 patients with severe acute pancreatitis, in 4 patients with mild acute pancreatitis (16%; CI, 4.5-36%), and in 30 patients with nonpancreatic acute abdomen (75%; CI, 59 -87%). Serum CRP concentrations were abnormally high in 12 patients with severe acute pancreatitis (80%; CI, 52-96%), in 13 patients with mild acute pancreatitis (52%; CI, 31-72%), and in 15 patients with nonpancreatic acute abdomen (38%; CI, 23-54%).
As shown in Table 3 , patients with severe acute pancreatitis had significantly higher serum concentrations of IL-6 than patients with mild acute pancreatitis (P Ͻ0.001) and healthy subjects (P Ͻ0.001), whereas no significant differences were found in comparison with patients having nonpancreatic acute abdomen. Patients with mild acute pancreatitis had significantly higher serum concentrations of IL-6 (P ϭ 0.009) than those of healthy subjects but significantly lower serum concentrations (P Ͻ0.001) than those of nonpancreatic acute abdomen. Patients with nonpancreatic acute abdomen had serum concentrations of this protein significantly higher (P Ͻ0.001) than those of healthy subjects.
Regarding serum CRP, patients with severe acute pancreatitis had serum concentrations of this protein that were not significantly different from patients with mild acute pancreatitis but significantly higher than patients with nonpancreatic acute abdomen (P ϭ 0.006) and healthy subjects (P Ͻ0.001). Both the patients with mild acute pancreatitis and those with nonpancreatic acute abdomen had significantly higher serum concentrations of CRP (P Ͻ0.001 and P ϭ 0.026, respectively) than those of healthy subjects; patients with nonpancreatic acute abdomen also had serum concentrations of CRP significantly higher (P ϭ 0.049) than those of patients with mild acute pancreatitis.
The ROC curves for serum lipase in differentiating between patients with acute pancreatitis and those with nonpancreatic acute abdomen, and for serum IL-6 and CRP in differentiating between the severe form and the mild form of acute pancreatitis, are shown in Fig. 2 . The values of the areas under the ROC curves (ϮSE) are 0.999 Ϯ 0.002 for serum lipase, 0.911 Ϯ 0.049 for serum IL-6, and 0.658 Ϯ 0.090 for serum CRP. The area of serum CRP was significantly lower (P ϭ 0.013) than that of serum IL-6. The best cutoff value of serum lipase to Table 3 . Serum concentrations of lipase, IL-6, and CRP in patients and healthy subjects. Clinical Chemistry 45, No. 10, 1999 differentiate between patients with acute pancreatitis and those patients with nonpancreatic acute abdomen ranged from 419 to 520 U/L. The best cutoff value to differentiate severe acute pancreatitis from the mild form of the disease was Ͻ3.7 g/L for IL-6 and ranged from 6 to 7 mg/L for CRP. In using lipase to discriminate between patients with nonpancreatic acute abdomen and patients with acute pancreatitis, one patient with mild acute pancreatitis, who had serum concentrations of lipase equal to 337 U/L, of IL-6 Ͻ2 g/L, and of CRP equal to 4 mg/L, was not identified correctly. In the remaining 39 patients, to distinguish those with severe acute pancreatitis from those with the mild form of the disease, a cutoff value Ͻ3.7 g/L for IL-6 had a sensitivity of 100% (15 of 15 severe acute pancreatitis; CI, 78 -100%) and a specificity of 83% (20 of 24 mild acute pancreatitis; CI, 63-95%). A total of 94% of the cases (severe acute pancreatitis ϩ mild acute pancreatitis ϩ nonpancreatic acute abdomen: 75 of 80; CI, 86 -98%) were classified correctly. CRP (cutoff between 6 and 7 mg/L) showed a lower prognostic efficiency than IL-6: sensitivity of 87% (13 of 15; CI, 60 -99%) and specificity of 46% (11 of 24; CI, 26 -67%); 80% of the cases (severe acute pancreatitis ϩ mild acute pancreatitis ϩ nonpancreatic acute abdomen: 64 of 80; CI, 70 -88%) were classified correctly.
Discussion
We found that serum lipase determination, using the upper limit of the reference interval (270 U/L), had a high sensitivity (100%) and specificity (93%) in differentiating acute pancreatitis from nonpancreatic acute abdomen. Using a cutoff value between 419 and 520 U/L, there was a slight decrease in sensitivity (98%) and an increase in specificity (100%); these results agree with those reported previously (10, 15, 16 ) . At present, many systems are used in determining the prognosis of acute pancreatitis (1, 2, 4, 17 ) ; these systems require clinical, laboratory, and radiological assessment of the disease, and none of them are useful for a rapid evaluation of high risk patients in emergency situations because they are expensive or time-consuming. It has been reported that serum concentrations of IL-6 increase in patients with inflammatory disorders (18 -25 ) and in patients with acute pancreatitis (4, 26 -29 ) ; however, there are no studies that used this molecule to establish the prognosis of acute pancreatitis at the first initial visit when the patient was in the Emergency Room. We have also found recently that the combined use of serum lipase either with CRP or with ␤ 2 -microglobulin is not useful in simultaneously establishing the diagnosis and the prognosis of acute pancreatitis (3 ) . In the present study, we evaluated whether the combined use of serum lipase and serum IL-6 assays, i.e., two tests that are quick and easy to perform, is able to serve this purpose. We also compared the sensitivity and the specificity of this combination with that of serum lipase and serum CRP.
Patients with severe acute pancreatitis, those with the mild form of the disease, and those with nonpancreatic acute abdomen had serum concentrations of both IL-6 and CRP significantly higher than those of the healthy subjects. These findings confirm previous studies (4, 5, 19, 21, 26 ) showing that in patients with acute pancreatitis and in those with nonpancreatic acute abdomen, there is early involvement of the immune system. The combined use of serum lipase and IL-6 allows us to simultaneously establish the diagnosis and the prognosis of acute pancreatitis in 94% of patients with acute abdomen, whereas the combined use of serum lipase and CRP had a lower performance (80%). These results may be because of the fact that, in acute pancreatitis patients, there is an activation of the acute phase response that is more pronounced in the severe form of the disease and involves proinflammatory cytokines such as IL-6 at an early stage (27 ) . On the contrary, CRP only indicates the severity of acute pancreatitis at a later stage because it requires the activation of cytokines for its synthesis by the liver (28, 29 ) .
In conclusion, the results of this study show that in emergency situations, it is now possible to simultaneously establish both the diagnosis and the prognosis of acute pancreatitis to put the high-risk patients in the intensive care unit and to immediately initiate intensive medical treatment. We hope that an IL-6 assay for routine use in emergency situations will be developed in the near future. Additional clinical studies involving a more consistent population of patients with acute pancreatitis are needed to confirm these initial and promising results.
